Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
St. Joseph's Healthcare Judy Dan Wound Care Centre, North York University Health Network, Toronto |
---|---|
Information provided by: | St. Joseph's Healthcare |
ClinicalTrials.gov Identifier: | NCT00621608 |
The purpose of this study is to determine if HBOT plus standard wound care is more effective than standard wound care alone at preventing the need for major amputation (metatarsal and up) in patients with diabetes mellitus (Type 1 or 2) with moderate to sever chronic wounds of lower limbs.
Condition | Intervention | Phase |
---|---|---|
Diabetes Mellitus Chronic Ulcers of the Lower Limb |
Procedure: Hyperbaric Oxygen Therapy Procedure: Placebo Hyperbaric Oxygen Chamber |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Prospective, Double-Blind, Randomized, Controlled Clinical Trial Comparing Standard Wound Care With Adjunctive Hyperbaric Oxygen Therapy (HBOT) to Standard Wound Care Only for the Treatment of Chronic, Non-Healing Ulcers of the Lower Limb in Patients With Diabetes Mellitus. |
Estimated Enrollment: | 118 |
Study Start Date: | April 2008 |
Estimated Study Completion Date: | December 2010 |
Estimated Primary Completion Date: | September 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Hyperbaric Oxygen Therapy
|
Procedure: Hyperbaric Oxygen Therapy
Hyperbaric Oxygen Therapy (HBOT) will be provided 5 days per week for 6 weeks for a total of 30 treatments on average. Subjects will be placed into the hyperbaric chamber for approximately 90 minutes of HBOT at 2.4 ATA (partial pressure of oxygen = 1,800 mmHg) when inside the chamber. Subjects will receive dressing changes as required per standard of care.
|
2: Sham Comparator
Placebo Hyperbaric Oxygen Chamber
|
Procedure: Placebo Hyperbaric Oxygen Chamber
Patients will receive HBOT placebo 5 days per week for 6 weeks for a total of 30 treatments. Each patient will be placed into the hyperbaric chamber and will receive 90 minutes of room air while inside the chamber and the initial flow of air into the chamber will produce a small increase in pressure (0.3 ATA partial pressure of oxygen = 210 mmHg) which will then be released over a period of 10 minutes. Subjects will receive dressings changes as required per standard of care.
|
People with diabetes mellitus and non-healing ulcers of the lower limb are at higher risk of amputation. Current standard care for foot ulcers includes maintaining optimal blood glucose levels, use of debridement, antibacterials, dressings, antibiotics for infection; adequate nutrition; pressure relief and amputation. There has been an increased interest in the use of hyperbaric oxygen therapy (HBOT) as an adjunctive treatment for diabetic ulcers. HBOT is an established technology which currently is an accepted treatment of chronic diabetic ulcers in Ontario and physicians who provide this service are reimbursed under the current Ontario Health Insurance Plan (OHIP). However there are only a few facilities that can provide this service. In addition, results of published HBOT studies are inconsistent. The current study will provide quality efficacy data on the use of HBOT as an adjunctive therapy. As this study has been recommended by the Ontario Health Technology Advisory Committee (OHTAC), the results of the study will be used to make policy decisions regarding the funding and further utilization of HBOT therapy for people with diabetes mellitus with ulcers of the lower limb in the province.
If the results are favorable towards HBOT in the treatment of diabetic ulcers, potential expansion and availability of this and other programs maybe be possible. A randomized placebo control trial evaluating HBOT, to the best of our knowledge has not been completed in this area and will provide much needed information to the scientific community.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Wilhelmine Jones, Reg. Nurse | 1-416-223-6600 | willie.jones@uhn.on.ca |
Contact: Ron Linden, MD | 1-416-223-6600 |
Canada, Ontario | |
Judy Dan Wound Care Centre/University Health Network | Recruiting |
Toronto, Ontario, Canada, M2R 1N5 | |
Principal Investigator: Ron Linden, MD | |
Principal Investigator: Ludwik Federko, MD |
Study Chair: | Daria O'Reilly, PhD | Programs for Assessment of Technology in Health Research Institute |
Principal Investigator: | Ludwik Fedorko, MD | Judy Dan Wound Care Centre/University Health Network |
Principal Investigator: | Ron Linden, MD | Judy Dan Wound Care Centre/University Health Network |
Responsible Party: | Programs for Assessment of Technology in Health Research Institute ( Ron Goeree, Director ) |
Study ID Numbers: | HTA011-0708-01 |
Study First Received: | January 29, 2008 |
Last Updated: | March 4, 2009 |
ClinicalTrials.gov Identifier: | NCT00621608 History of Changes |
Health Authority: | Canada: Health Canada |
Chronic ulcers Diabetes Hyperbaric Oxygen Therapy |
Metabolic Diseases Ulcer Diabetes Mellitus Endocrine System Diseases |
Endocrinopathy Glucose Metabolism Disorders Metabolic Disorder |
Pathologic Processes Metabolic Diseases Ulcer |
Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders |